logo amu logo cnrs

UMR 7286 - Centre de Recherche en Neurobiologie et Neurophysiologie de Marseille

Plates-formes PFRN

Accueil > Bibliographie > Genetic screening of combined pituitary hormone deficiency : experience in (...)

Genetic screening of combined pituitary hormone (...)

J Clin Endocrinol Metab. 2006 Sep ;91(9):3329-36
Genetic screening of combined pituitary hormone deficiency : experience in 195 patients.
Reynaud R, Gueydan M, Saveanu A, Vallette-Kasic S, Enjalbert A, Brue T, Barlier A.

CONTEXT : Mutations in transcription factors result in combined pituitary hormone deficiency (CPHD). OBJECTIVE : A genetic screening strategy, based on endocrine and neuroradiological phenotype according to published knowledge, was applied to establish the prevalence of gene defects in each category of patients and provide a useful framework for clinicians to determine the genetic etiology and recurrence risks for individuals and families. DESIGN : One hundred ninety-five CPHD patients from the international GENHYPOPIT network were studied, according to their phenotype, for POU1F1, PROP1, LHX3, LHX4, and HESX1. PATIENTS : Patients selected had two pituitary hormone deficiencies or at least one deficiency with intracerebral malformations. RESULTS : Total prevalence of mutations was 13.3 and 52.4% in 20 patients with familial CPHD history. No mutation of HESX1 was observed in 16 patients harboring septooptic dysplasia. A mutation of LHX4 gene, previously reported, was found in one familial case from 39 patients bearing pituitary stalk interruption syndrome. In 109 patients without extrapituitary abnormalities, 20 had PROP1 mutations, including eight patients with a family history of CPHD. Among 20 patients without pituitary stalk interruption syndrome, no LHX3 gene defect was found, even with a neck rotation deficit. One POU1F1 gene defect was found in one patient presenting the rare postpubertal association of thyrotroph (TSH deficiency) and somatotroph (GH deficiency) deficits. CONCLUSIONS : Mutation of PROP1 gene remains the first to be looked for, and POU1F1 mutations should be sought in GH deficiency and TSH deficiency postpubertal population without extrapituitary malformations. Identification of gene defects allows early treatment of any deficit and prevention of their potentially fatal consequences. Genotyping appears highly beneficial at an individual and familial level.


Le CRN2M en chiffres

  • 20 Chercheurs
  • 19 Enseignants Chercheurs
  • 39 ITAs et IATOs
  • 3 Post-Docs
  • 5 Docs
  • 4 Étudiants de Master

    Ils nous font confiance

  • logo amu
  • logo cnrs
  • logo inserm
  • logo AP-HM
  • logo Galderma
  • logo Ipsem
  • logo Novartis
  • logo Pfizer
  • logo Fédération pour la Recherche sur le Cerveau
  • logo Fondation pour la Recherche Medical en France
  • logo IBiSA
  • logo Europe programme FEDER
  • logo Agence Nationale de la Recherche